Table 3.

The net benefit and the proportion of unnecessary biopsies reduced for PSAD, mpMRI, and the model in cohort 2

Risk threshold, %	Net benefit				Avoided biopsies
	All biopsies	PSAD	MRI	Model	PSAD	MRI	Model
10	0.412	0.412	0.413	0.405	0	0.45%	−6.75%
20	0.339	0.369	0.382	0.394	12.04%	17.32%	22.12%
30	0.245	0.313	0.342	0.381	16.03%	22.91%	31.73%
40	0.119	0.239	0.290	0.362	18.03%	25.37%	36.54%